MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas.
about
Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a referenceO(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problemsDNA methylation biomarkers: cancer and beyondOligodendroglioma: pathology, molecular mechanisms and markersMGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.Alterations of copy number of methylation pattern in mismatch repair genes by methylation specific-multiplex ligation-dependent probe amplification in cases of colon cancerMolecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug developmentCorrelation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MS-MLPA in patients with glioblastoma multiforme.Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas.First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBMO6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction.Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapiesMethylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome.Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomideThe combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancerCritical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerationsMGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation.A study of genomic instability in early preneoplastic colonic lesions.Altered expression of MGMT in high-grade gliomas results from the combined effect of epigenetic and genetic aberrations.Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients.Multiplexed methylation profiles of tumor suppressor genes in bladder cancer.Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markersHPV-positive oropharyngeal squamous cell carcinoma is associated with TIMP3 and CADM1 promoter hypermethylation.Integrated analysis of mismatch repair system in malignant astrocytomas.VRK2 identifies a subgroup of primary high-grade astrocytomas with a better prognosisThe use of a two-tiered testing strategy for the simultaneous detection of small EGFR mutations and EGFR amplification in lung cancer.The prognostic role of preoperative serum albumin levels in glioblastoma patients.Volumetric and MGMT parameters in glioblastoma patients: survival analysis.MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCRUse of the MLPA assay in the molecular diagnosis of gene copy number alterations in human genetic diseases.MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study.Breast carcinoma and Lynch syndrome: molecular analysis of tumors arising in mutation carriers, non-carriers, and sporadic cases.The Changes in MGMT Promoter Methylation Status in Initial and Recurrent GlioblastomasPrimary and recurrent diffuse astrocytomas: genomic profile comparison reveals acquisition of biologically relevant aberrationsDARPP32, STAT5 and STAT3 mRNA expression ratios in glioblastomas are associated with patient outcome.Clinical neuropathology practice guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkersMethylated DNA and microRNA in body fluids as biomarkers for cancer detection.Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in oligodendroglial tumors.
P2860
Q21261312-D3959ED1-6D5B-444C-9614-E9C4E07A9190Q26853112-F1CE436E-0234-4AF0-9694-B5A2CC49D9F6Q26996421-22B4DB33-B7F9-45A3-9EEC-CCC18E3E403AQ27002448-C0F6EA45-416C-4098-9B63-88A2AE90D2DDQ27851529-3FD7A509-6CEE-4CC4-A7F0-C5888D934E95Q28298882-530B2590-BEE8-46F7-B768-9FAA7C10D61DQ28475285-541B84CF-8621-4A06-8F2F-1F42B2927289Q30571373-95DE2970-B380-48C5-AD37-F939921A1C9EQ33671442-2CB3525C-DF2D-4DB3-95C4-EC3D8B71489DQ33777877-5F7B85F6-502E-474C-AD8C-E3E931A8A2A8Q33797741-332E28DF-5853-42B0-B349-DE4C9B5C438EQ33804528-48F907BE-CE96-4083-8AF1-6397A27BA969Q33925544-CEFFE360-5131-4BB1-AF63-B9A43496C316Q33947093-4C504632-1443-4673-A446-52A8ADF27E46Q34000287-2C6799E2-B1E5-4783-BCCF-563FFD918BD8Q34061985-381D0D62-3E9A-403D-AE4C-CE32460DB41CQ34202639-47955ECA-CFCD-49E9-AB8C-6B915C25F431Q34418437-E1211411-CED9-4B4F-A32C-8D728E3DF17DQ34507966-DF43B1A7-1E60-4D1F-853B-7DA8E47EA4CFQ34514570-3D9E1389-2771-467E-AF76-E183D9F634C0Q34625644-C3678F49-0CE9-4BDC-AF5D-D41D665503F0Q34722521-EE6A864E-A460-452E-B457-2CA8A6F772C8Q34760755-19626873-9249-4AE3-A1C6-C1F7AFAC73E6Q34815207-8C27E94F-E824-47CB-ACA7-36E8F952850CQ34998465-511C2AAB-4D19-402B-B42D-3E43B98ADBE4Q35000971-63DD6614-EA85-4A86-B98D-3AE5D38F8BB8Q35002396-2124299B-1B44-4F90-B59C-1AEA684C4D8CQ35125795-EE56CB6A-5298-4626-AA7C-D6AA46C6FFD3Q35164608-FC1E8420-56A5-45B3-A8FC-1FF95C3B7480Q35689991-CF8A4FCD-95D2-4D00-9099-9C4BC661FFC4Q35850389-201033E8-5917-4A23-BEA8-EEB2D82BAA47Q35866022-822C08E7-C23A-4E5E-8104-F3C43CD56F65Q36035692-E1924F49-71BE-427A-A592-0DB9BD4684B1Q36245422-1A6A7A5C-ED8C-47EF-809D-581B4577EAEFQ36310665-E0CD192D-EE65-49E1-A3EB-26771DEB6D70Q36566055-E2494DFB-FEBF-434F-8C90-D5FA27C0B729Q36755933-C76787EC-0523-4680-B9F0-8AD72A14EB3EQ36873451-632443B1-0463-4BEF-8B17-A4A000FA24DDQ36913739-DD115A4B-FB68-4256-8158-94F6F527209AQ37148924-ADE6A5E1-E4D1-4BFA-8DDB-9ECA37C7B546
P2860
MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
MS-MLPA: an attractive alterna ...... r hypermethylation in gliomas.
@en
type
label
MS-MLPA: an attractive alterna ...... r hypermethylation in gliomas.
@en
prefLabel
MS-MLPA: an attractive alterna ...... r hypermethylation in gliomas.
@en
P2093
P1476
MS-MLPA: an attractive alterna ...... r hypermethylation in gliomas.
@en
P2093
Abdellatif Errami
Angelique Sijben
Judith W M Jeuken
Marieke M G Dekkers
Martine Vriezen
Pieter Wesseling
Sandra H E Boots-Sprenger
Sandra J B Cornelissen
P2888
P304
P356
10.1038/LABINVEST.3700664
P577
2007-08-13T00:00:00Z